Skip to content

Labcorp Holdings LH Diagnostics — Goodwill

Other segment segments

Biopharma Laboratory Services
$1.35B

Similar metrics at other companies

Opko Health logo
OPKDiagnostics — Goodwill
$163.44M0.0%
Revvity logo
RVTYDiagnostics — Goodwill
$1.86B-4.0%
Revvity logo
RVTYDiagnostics — Goodwill, Acquisition
$0
Danaher logo
DHRDiagnostics — Goodwill
$6.96B+1.8%
Bio-Rad Laboratories logo
BIOClinical Diagnostics — Goodwill, net
$128.4M+4.3%
Thermo Fisher Scientific logo
TMOSpecialty Diagnostics — Goodwill
$5.08B+6.1%

Other financials

Income statement

See full
Revenue$3.5B+5.8%
Gross profit$1.0B+6.9%
Operating income$380.8M+16.8%
Net income$277.8M+30.5%
EPS (diluted)$3.35+32.9%

Balance sheet

See full
Cash & equivalents$981.1M+166%
Total debt$7.2B+11.1%
Total equity$8.7B+5.1%
Total assets$19.1B+8.4%

Cash flow

See full
Operating cash flow$191.5M+935%
CapEx$121.0M-4.0%
Free cash flow$70.5M+166%

Valuation

See full
Market cap$22.96B+9.4%
Enterprise value$29.22B+10.7%
P/E24.4×-3.1×
P/S1.6×+0.1×

Profitability

See full
Gross margin28.8%+0.9pp
Operating margin10.2%+1.9pp
Net margin6.7%+1.1pp
FCF margin9.8%+1.0pp

Returns & leverage

See full
Return on equity11.1%+2.1pp
Debt / equity0.8×0.0×
Current ratio1.7×-0.1×

Where this comes from

Reported directly by Labcorp Holdings in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Labcorp Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Labcorp Holdings's diagnostics — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Labcorp Holdings's diagnostics — goodwill?
Labcorp Holdings (LH) reported diagnostics — goodwill of $5.61B in Q1 2026.
What does diagnostics — goodwill mean?
This represents the intangible asset value recorded when the diagnostics segment acquires other businesses for a price exceeding the fair market value of their net identifiable assets. It reflects the premium paid for synergies, brand reputation, and market share expansion within the diagnostics space.